Anti-Human ITGB2 Therapeutic Antibody (23F2G)

This antibody immunologically reacts with the common β chain (CD18) of human leukocyte integrins and/or competes with mAb 60.3 for binding to human LFA-1, which is useful for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory processes associated with the multiple sclerosis disease.
Supplier Creative Biolabs
Product # TAB-1581CL
Pricing Inquiry
Host Mouse
Target CD18
Feedback